Three Products Featuring TCL CSOT Displays Named to TIME's Best Inventions of 2026

SHENZHEN, China, Oct. 30, 2026 /PRNewswire/ -- TCL's flagship X11L SQD-Mini LED TV, the XTEINK X4 Pro Pocket eReader and the Framework Laptop 13 Pro have been named to TIME's Best Inventions of 2026 list. All three products feature displays supplied by TCL CSOT.

TCL X11L: Advancing Large-Screen Picture Quality

As the only Chinese TV selected in the consumer electronics category of TIME's Best Inventions of 2026, the TCL X11L features the TCL CSOT WHVA 2.0 Ultra Panel, delivering a native contrast ratio of 7,000:1 and 100% BT.2020 color space coverage. Its display technology combines the TCL CSOT Ultra Color Filter with 20,736 Precise Dimming Zones and 10,000-nit peak HDR brightness. Powered by SQD-Mini LED technology, which delivers an industry-leading color gamut, the X11L captures subtle variations in light, further advancing large-screen picture quality.

In its Best Inventions of 2026 coverage, TIME noted that "those who manufacture TVs are constantly seeking new ways to one-up their competitors, either through unique design or unmatchable image quality." The TCL X11L, the publication stated, "promises the latter with an LED panel that employs 'super quantum dot' technology, designed with the capacity to emit light at more specific nanometer wavelengths than previously available tech. The resulting image is extremely color accurate but also impressively bright."

XTEINK X4 Pro: Bringing Reading to Your Pocket

The XTEINK X4 Pro features a 4.3-inch E Ink display that uses reflective imaging technology and emits no blue light, delivering a paper-like reading experience designed to reduce eye fatigue during extended use. Its capacitive touchscreen and adjustable warm-and-cool front lighting help provide comfortable reading conditions throughout the day and night.

TIME wrote, "While the most popular e-readers are smaller than a hardcover, many are still a bit too large for true grab-and-go convenience. XTEINK filled the gap with its X3 and X4 e-readers." Beyond its compact size, the XTEINK X4 Pro further enhances the reading experience with an upgraded, higher-capacity battery, making pocket-sized reading convenient at any time of day or night.

Framework Laptop 13 Pro: A Repairable, Upgradeable Laptop

The Framework Laptop 13 Pro combines a modular, repairable design with a custom 13.5-inch 2.8K touchscreen supplied by TCL CSOT. The display module measures 2.0 mm thick on the device side and 2.1 mm on the PCB side, with a weight of only 180 g, supporting the laptop's modular architecture. The updated model also features a 74 Wh battery and a haptic trackpad, while its modular design allows users to replace or upgrade components and customize their configuration, from memory and keyboard options to ports.

TIME recognized the laptop for making high-performance computing more repairable and user-customizable. The newly updated Framework Laptop 13 Pro is more "like a bicycle," says Framework CEO Nirav Patel. "Every part is easy to replace." With an included screwdriver and components designed for replacement and upgrades, the laptop enables users to repair and personalize their devices themselves, and help extend product lifespan. By putting repair and customization in users' hands, the Framework Laptop 13 Pro offers a more flexible and sustainable approach to personal computing.

The inclusion of all three products in TIME's Best Inventions of 2026 highlights not only the strength of each product, but also TCL CSOT's end-to-end capabilities from technology R&D to industry collaboration. Looking ahead, TCL CSOT will continue to advance multiple display technology pathways and collaborate with industry partners to expand applications across diverse scenarios, bringing high-quality, slim, eye-care and environmentally friendly display solutions to more users.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Three Products Featuring TCL CSOT Displays Named to TIME's Best Inventions of 2026

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"